Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.

Abstract:

:Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. Of note, malignant tumor urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor levels have been found to vary considerably, and to be related to patient prognosis. In mouse models, the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been studied extensively as a target for anticancer therapy using a variety of approaches. In this review, we discuss the advances in the various modalities that have been used to target the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system, including protein-based and peptide-based drugs, antisense therapy, and RNA interference technology. In particular, preclinical mouse model studies that used human tumor xenografts are reviewed.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Ohara T,Yamamoto E

doi

10.1097/01.cad.0000231483.09439.3a

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

1109-17

issue

10

eissn

0959-4973

issn

1473-5741

pii

00001813-200611000-00001

journal_volume

17

pub_type

杂志文章,评审
  • Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.

    abstract::Mistletoe extracts are frequently applied in adjuvant cancer treatment. The mistletoe lectins are especially suggested to mediate an antitumorous effect. During treatment with mistletoe lectin-rich extracts, anti-mistletoe lectin antibodies preferentially of the immunoglobulin G type are produced against mistletoe lec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199704001-00013

    authors: Stein GM,Stettin A,Schultze J,Berg PA

    更新日期:1997-04-01 00:00:00

  • Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.

    abstract::Acquired docetaxel (Doc) resistance in hormone-refractory prostate cancer (HRPC) remains an ongoing clinical challenge, resulting in failed chemotherapy and tumor recurrence. However, the mechanism of Doc-resistance development in prostate cancer cells is still unclear. Here, we observed a subpopulation of prostate ca...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000659

    authors: Qiu S,Deng L,Bao Y,Jin K,Tu X,Li J,Liao X,Liu Z,Yang L,Wei Q

    更新日期:2018-10-01 00:00:00

  • Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis.

    abstract::Esophageal cancer is one of the fatal cancers around the world. Dexmedetomidine (DEX) is widely used during anesthesia of esophageal cancer surgery. Nevertheless, the role of DEX in the progression of esophageal cancer remains barely known. The proliferation, apoptosis and metastasis of esophageal cancer cells were de...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000934

    authors: Zhang P,He H,Bai Y,Liu W,Huang L

    更新日期:2020-08-01 00:00:00

  • NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.

    abstract::We recently established that NCPMF-60, a newly synthesized flavonoid, is an active cytotoxic component. The molecular mechanisms by which NCPMF-60 exerts its cytotoxic activity are currently unknown. In this study, we show that NCPMF-60 induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma HepG2 ce...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283405801

    authors: Dai QS,Liu W,Wang XB,Lu N,Gong DD,Kong LY,Guo QL

    更新日期:2011-01-01 00:00:00

  • Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells.

    abstract::STAT5 is an important transcription factor that is constitutively activated in various types of malignancies, including chronic myelogenous leukemia (CML). Whether the antitumor effects of resveratrol (RES) are linked to its capability to inhibit STAT5 activation in CML cells was investigated. We found that RES inhibi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000635

    authors: Li Q,Zhang L,Ma L,Bai X,Li X,Zhao M,Sui T

    更新日期:2018-08-01 00:00:00

  • A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.

    abstract::Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we s...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199010000-00011

    authors: Baghdiguian S,Nickel P,Marvaldi J,Fantini J

    更新日期:1990-10-01 00:00:00

  • Chemotherapy for recurrent/metastatic head and neck cancers.

    abstract::Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this pr...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000473

    authors: Karabajakian A,Toussaint P,Neidhardt EM,Paulus V,Saintigny P,Fayette J

    更新日期:2017-04-01 00:00:00

  • Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.

    abstract::Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834bede5

    authors: Pouessel D,Culine S

    更新日期:2012-01-01 00:00:00

  • The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.

    abstract::Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar resul...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000504

    authors: Borges KS,Andrade AF,Silveira VS,Marco Antonio DS,Vasconcelos EJR,Antonini SRR,Tone LG,Scrideli CA

    更新日期:2017-07-01 00:00:00

  • Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.

    abstract::Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199709000-00005

    authors: Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

    更新日期:1997-09-01 00:00:00

  • Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients.

    abstract::Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199605000-00006

    authors: Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

    更新日期:1996-05-01 00:00:00

  • Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.

    abstract::Gefitinib (an epidermal growth factor receptor tyrosine kinase inhibitor) and bexarotene (a rexinoid) affect similar oncogenic pathways and are both metabolized through cytochrome P450 CYP3A4. We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to e...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32836100d7

    authors: Padda SK,Chhatwani L,Zhou L,Jacobs CD,Lopez-Anaya A,Wakelee HA

    更新日期:2013-08-01 00:00:00

  • Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect.

    abstract::The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199611000-00007

    authors: Inoue T,Yang DJ,Wallace S,Cherif A,Tansey W,Kim EE,Hunter N,Milross CG,Milas L,Podoloff DA

    更新日期:1996-11-01 00:00:00

  • Para-toluenesulfonamide induces tongue squamous cell carcinoma cell death through disturbing lysosomal stability.

    abstract::Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000283

    authors: Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

    更新日期:2015-11-01 00:00:00

  • A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.

    abstract::9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199801000-00004

    authors: Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

    更新日期:1998-01-01 00:00:00

  • Ifosfamide in pediatric oncology.

    abstract::Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199108000-00002

    authors: de Kraker J

    更新日期:1991-08-01 00:00:00

  • Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction.

    abstract::A combined treatment with conventional chemotherapies can enhance the effectiveness of chemotherapeutic agents against cancers. Here, we have shown that the naturally occurring triterpenoids synergistically enhance the response of cervical cancer cells to taxol. Of the triterpenoid compounds, pristimerin enhanced the ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328347181a

    authors: Eum DY,Byun JY,Yoon CH,Seo WD,Park KH,Lee JH,Chung HY,An S,Suh Y,Kim MJ,Lee SJ

    更新日期:2011-09-01 00:00:00

  • Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.

    abstract::Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283212ade

    authors: Chen H,Sun B,Pan S,Jiang H,Sun X

    更新日期:2009-02-01 00:00:00

  • Doxycycline and other tetracyclines in the treatment of bone metastasis.

    abstract::The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200311000-00001

    authors: Saikali Z,Singh G

    更新日期:2003-11-01 00:00:00

  • Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.

    abstract::OncoGel is a novel depot formulation of paclitaxel designed for intralesional injection with a sustained paclitaxel delivery over approximately 6 weeks from a single administration. This phase 1 study was designed to characterize the toxicity, pharmacokinetics and preliminary antitumor activity associated with OncoGel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328011a51d

    authors: Vukelja SJ,Anthony SP,Arseneau JC,Berman BS,Cunningham CC,Nemunaitis JJ,Samlowski WE,Fowers KD

    更新日期:2007-03-01 00:00:00

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice.

    abstract::The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against carcinomatous peritonitis in mice. In the first experiment using carcinomatous peritonitis caused by i.p. inoculation of 10(6) M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body weight into two grou...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199506000-00012

    authors: Tsujimoto H,Hagiwara A,Osaki K,Ohyama T,Sakakibara T,Sakuyama A,Ohgaki M,Imanishi T,Watanabe N,Yamazaki J

    更新日期:1995-06-01 00:00:00

  • 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.

    abstract::1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200006000-00004

    authors: Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

    更新日期:2000-06-01 00:00:00

  • Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.

    abstract::Prostaglandin E2 (PGE2) has been shown to play an important role in tumor development and progression. PGE2 mediates its biological activity by binding any one of four prostanoid receptors (EP1 through EP4). The present study was designed to determine the role of the EP2 receptor during the proliferation and apoptosis...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835a4dac

    authors: Hu S,Sun W,Wei W,Wang D,Jin J,Wu J,Chen J,Wu H,Wang Q

    更新日期:2013-02-01 00:00:00

  • Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.

    abstract::Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer. The risk of secondary leukaemia is well described after mitoxantrone treatment in breast cancer and multiple sclerosis. Recent improvements of systemic chemotherapy increased the median survival in pati...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3280113324

    authors: Martinez V,Mir O,Dômont J,Bouscary D,Goldwasser F

    更新日期:2007-02-01 00:00:00

  • L-Methionine inhibits growth of human pancreatic cancer cells.

    abstract::We have previously shown that L-methionine inhibits proliferation of breast, prostate, and colon cancer cells. This study extends these findings to BXPC-3 (mutated p53) and HPAC (wild-type p53) pancreatic cancer cells and explores the reversibility of these effects. Cells were exposed to L-methionine (5 mg/ml) for 7 d...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000038

    authors: Benavides MA,Bosland MC,da Silva CP,Gomes Sares CT,de Oliveira AM,Kemp R,dos Reis RB,Martins VR,Sampaio SV,Bland KI,Grizzle WE,dos Santos JS

    更新日期:2014-02-01 00:00:00

  • Intra-abdominal desmoplastic small cell tumors: report of two cases.

    abstract::Two young adults that presented with intra-abdominal desmoplastic small cell tumors (DSCT) without any evidence of a primary site are described. Both cases share the clinical characteristic features of this rare tumor which include predominant intra-abdominal location as initial presentation, nesting pattern of growth...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Liau CT,Yang TS,Wang CH,Hsueh S

    更新日期:1996-02-01 00:00:00

  • Proceedings of the First International Conference on PEP005.

    abstract::The sap of Euphorbia peplus, commonly know as 'petty spurge', 'radium weed' or 'milkweed' has been used for centuries as a traditional treatment for skin conditions, including warts, corns and cancers of the skin. Documentation of its use by medical professionals to treat basal cell carcinoma (BCC) dates from the earl...

    journal_title:Anti-cancer drugs

    pub_type:

    doi:10.1097/CAD.0b013e3280149ec5

    authors: Ogbourne SM,Hampson P,Lord JM,Parsons P,De Witte PA,Suhrbier A

    更新日期:2007-03-01 00:00:00

  • Apoptosis induced by desmethyl-lasiodiplodin is associated with upregulation of apoptotic genes and downregulation of monocyte chemotactic protein-3.

    abstract::There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283635a47

    authors: Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

    更新日期:2013-09-01 00:00:00

  • Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells.

    abstract::Gallbladder carcinoma is the most common malignancy of the biliary tract and is associated with a very poor outcome. The aim of the present study was to investigate the effects of oxymatrine (OM) on gallbladder cancer cells and the possible mechanism of its effects. The effects of OM on the proliferation of gallbladde...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000124

    authors: Wu XS,Yang T,Gu J,Li ML,Wu WG,Weng H,Ding Q,Mu JS,Bao RF,Shu YJ,Cao Y,Wang XA,Ding QC,Dong P,Xie SF,Liu YB

    更新日期:2014-10-01 00:00:00

  • Chemotherapy versus palliative care in non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of symptoms and extension of life. A substantial body of evidence has eme...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200009000-00001

    authors: Nicum S,Cullen MH

    更新日期:2000-09-01 00:00:00